Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
GeneDx Holdings Corp. incurred term loan of $100.0 million with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative”) at Term SOFR adjusted secured overnight financing rate plus a margin of 4.50% maturing five years from the Closing Date.
- Instrument
- term loan
- Principal
- $100.0 million
- Counterparty
- Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative”)
- Rate
- Term SOFR adjusted secured overnight financing rate plus a margin of 4.50%
- Maturity
- five years from the Closing Date
- Event
- incurrence
Exact text from the filing
The Loan Agreement provides for a term loan in an aggregate principal amount of $100.0 million funded to the Company on the Closing Date (the “Term Loan”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GeneDx Holdings Corp. terminated Existing Credit Agreement with Perceptive Credit Holdings IV, LP valued at Repayment in full of existing term loan (effective 2026-02-27).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Perceptive Credit Holdings IV, LP
- Value
- Repayment in full of existing term loan
- Effective
- 2026-02-27
Exact text from the filing
The proceeds of the Term Loan were used to repay in full the Company’s existing term loan under its existing Credit Agreement and Guaranty, dated as of October 27, 2023, by and among Sema4 OpCo, Inc. and GeneDx, LLC, as Borrowers, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP as the administrative agent and as a lender (the “Existing Credit Agreement”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GeneDx Holdings Corp. entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. valued at $100.0 million term loan (effective 2026-02-27).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.
- Value
- $100.0 million term loan
- Effective
- 2026-02-27
Exact text from the filing
On February 27, 2026 (the “Closing Date”), GeneDx Holdings Corp. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”), with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries of the Company party thereto as Guarantors, Wilmington Trust, National Association, as Agent and the lenders from time to time party thereto (collectively, the “Lenders”).
View on SEC.gov